Epacadostat
- Generic Name
- Epacadostat
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Conditions
- Advanced MalignanciesSolid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT02959437
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
- Conditions
- NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02862457
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
- Conditions
- Recurrent Fallopian Tube CancerRecurrent Peritoneal CancerRecurrent Epithelial Ovarian Cancer
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Target Recruit Count
- 85
- Registration Number
- NCT02785250
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-resistant Fallopian CancerPlatinum-resistant Peritoneal Cancer
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02575807
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT02559492
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
- Conditions
- Thymic CarcinomaThymus CancerThymus Neoplasms
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 45
- Registration Number
- NCT02364076
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
- Conditions
- Ovarian CancerHead and Neck CancerLung CancerMelanomaB-cell MalignanciesColorectal Cancer (CRC)LymphomaGlioblastoma
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 307
- Registration Number
- NCT02327078
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
- Conditions
- UC (Urothelial Cancer)Head and Neck CancerLung CancerSolid Tumors
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 176
- Registration Number
- NCT02318277
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
- Conditions
- UC (Urothelial Cancer)NSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02298153
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Head and Neck CancerMelanomaEndometrial CancerLung CancerRenal Cell Carcinoma (RCC)Bladder CancerGastric CancerOvarian CancerLymphoma
- Interventions
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 444
- Registration Number
- NCT02178722
- Locations
- 🇺🇸
University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Greater Baltimore Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.